Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
1.
Stem Cell Res ; 73: 103211, 2023 12.
Article in English | MEDLINE | ID: mdl-37890334

ABSTRACT

The most common cause of autosomal recessive familial Parkinson's disease (PD) are mutations in the PRKN/PARK2 gene encoding an E3 ubiquitin protein-ligase PARKIN. We report the generation of an iPSC cell line from the fibroblasts of a male PD patient carrying a common missense variant in exon 7 (p.Arg275Trp), and a 133 kb deletion encompassing exon 8, using transiently-present Sendai virus. The established line displays typical human primed iPSC morphology and expression of pluripotency-associated markers, normal karyotype without SNP array-detectable copy number variations and can give rise to derivatives of all three embryonic germ layers. We envisage the usefulness of this iPSC line, carrying a common and well-studied missense mutation in the RING1 domain of the PARKIN protein, for the elucidation of PARKIN-dependent mechanisms of PD using in vitro and in vivo models.


Subject(s)
Induced Pluripotent Stem Cells , Parkinson Disease , Humans , Male , Induced Pluripotent Stem Cells/metabolism , Parkinson Disease/genetics , Parkinson Disease/metabolism , DNA Copy Number Variations , Mutation/genetics , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/metabolism
2.
Hum Reprod ; 34(4): 751-757, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30865256

ABSTRACT

STUDY QUESTION: Does an informed group of citizens endorse the clinical use of mitochondrial donation in a country where this is not currently permitted? SUMMARY ANSWER: After hearing balanced expert evidence and having opportunity for deliberation, a majority (11/14) of participants in a citizens' jury believed that children should be able to be born using mitochondrial donation. WHAT IS KNOWN ALREADY: Research suggests that patients, oocyte donors and health professionals support mitochondrial donation to prevent transmission of mitochondrial disease. Less is known about public acceptability of this novel reproductive technology, especially from evidence using deliberative methods. STUDY DESIGN, SIZE, DURATION: This study comprised a citizens' jury, an established method for determining the views of a well-informed group of community members. The jury had 14 participants, and ran over one and a half days in 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: Jurors were members of the public with no experience of mitochondrial disease. They heard and engaged with relevant evidence and were asked to answer the question: 'Should Australia allow children to be born following mitochondrial donation?' MAIN RESULTS AND THE ROLE OF CHANCE: Eleven jurors decided that Australia should allow children to be born following mitochondrial donation; 7 of whom added conditions such as the need to limit who can access the intervention. Three jurors decided that children should not (or not yet) be born using this intervention. All jurors were particularly interested in the reliability of evidence, licensing/regulatory mechanisms and the rights of children to access information about their oocyte donors. LIMITATIONS, REASONS FOR CAUTION: Jurors' views were well informed and reflected critical deliberation and discussion, but are not intended to be representative of the whole population. WIDER IMPLICATIONS OF THE FINDINGS: When presented with high quality evidence, combined with opportunities to undertake structured deliberation of novel reproductive technologies, members of the public are able to engage in detailed discussions. This is the first study to use an established deliberative method to gauge public views towards mitochondrial donation. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by a University of Sydney Industry and Community Collaboration Seed Award (2017), which was awarded contingent on additional funding from the Mito Foundation. Additional funding was provided by the Mito Foundation. The Foundation was not involved in jury facilitation or deliberation, nor analysis of research data. TRIAL REGISTRATION NUMBER: Not applicable.


Subject(s)
Attitude , Mitochondrial Diseases/prevention & control , Mitochondrial Replacement Therapy/legislation & jurisprudence , Mitochondrial Replacement Therapy/methods , Oocyte Donation/legislation & jurisprudence , Oocyte Donation/methods , Public Opinion , Adolescent , Adult , Aged , Australia , Decision Making , Female , Humans , Male , Middle Aged , Policy Making , Young Adult
3.
J Neurol ; 262(10): 2323-8, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26194196

ABSTRACT

Pathogenic mutations in the OPA1 gene can be associated with Autosomal Dominant Optic Atrophy (ADOA). In approximately 20 % of patients with OPA1 mutations, a more complex neurodegenerative disorder with extraocular manifestations, known as ADOA Plus, can arise. 12 members of a multigenerational family were assessed clinically and screened for a genetic mutation in OPA1. Eight family members displayed manifestations consistent with ADOA Plus and four did not. Affected members of the oldest available generation displayed the most severe phenotype, which included severe optic atrophy, deafness, ptosis, ophthalmoplegia, proximal myopathy, neuropathy and ataxia. The next generation was less severely affected but several members displayed manifestations only after the fifth decade. Genetic analysis revealed a heterozygous variant in the OPA1 gene (c.1053T>A, p.Asp351Glu) that segregated with disease. The affected family members described here exhibited visual loss later than is typical for OPA1-related disease, as well as later onset of other neurological abnormalities in the fifth or sixth decades of life that progressed to severe neurological disability by the seventh decade. These findings expand the clinical spectrum of OPA1-related disease associated with a novel OPA1 mutation.


Subject(s)
GTP Phosphohydrolases/genetics , Optic Atrophy, Autosomal Dominant/genetics , Optic Atrophy, Autosomal Dominant/physiopathology , Adult , Aged , Australia , Female , Humans , Male , Mutation , Pedigree , Phenotype
4.
Eur J Neurol ; 22(5): 826-31, e57-8, 2015 May.
Article in English | MEDLINE | ID: mdl-25683471

ABSTRACT

BACKGROUND AND PURPOSE: Cortical hyperexcitability has been identified as an important pathogenic mechanism in motor neuron disease (MND). The issue as to whether cortical hyperexcitability is a common process across the MND phenotypes, including amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS), remains unresolved. Separately, the clinical distinction between PLS and 'mimic disorders' such as hereditary spastic paraparesis (HSP) may be difficult, potentially delaying diagnosis. Consequently, the aim of the present study was to determine the nature and spectrum of cortical excitability changes across the MND phenotypes, and to determine whether the presence of cortical dysfunction distinguishes PLS from HSP. METHODS: Cortical excitability studies were undertaken on a cohort of 14 PLS, 82 ALS and 13 HSP patients with mutations in the spastin gene. RESULTS: Cortical hyperexcitability, as heralded by reduction of short interval intracortical inhibition (PLS 0.26%, -3.8% to 1.4%; ALS -0.15%, -3.6% to 7.0%; P < 0.01) and cortical silent period duration (CSPPLS 172.2 ± 5.4 ms; CSPALS 178.1 ± 5.1 ms; P < 0.001), along with an increase in intracortical facilitation was evident in ALS and PLS phenotypes, although appeared more frequently in ALS. Inexcitability of the motor cortex was more frequent in PLS (PLS 71%, ALS 24%, P < 0.0001). Cortical excitability was preserved in HSP. CONCLUSIONS: Cortical dysfunction appears to be an intrinsic process across the MND phenotypes, with cortical inexcitability predominating in PLS and cortical hyperexcitability predominating in ALS. Importantly, cortical excitability was preserved in HSP, thereby suggesting that the presence of cortical dysfunction could help differentiate PLS from HSP in a clinical setting.


Subject(s)
Cerebral Cortex/physiopathology , Electrophysiological Phenomena/physiology , Motor Neuron Disease/physiopathology , Spastic Paraplegia, Hereditary/physiopathology , Adenosine Triphosphatases/genetics , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Motor Cortex/physiopathology , Phenotype , Spastic Paraplegia, Hereditary/genetics , Spastin , Young Adult
5.
Endocr Relat Cancer ; 21(3): 415-26, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24623741

ABSTRACT

miR-210 is a key regulator of response to hypoxia. Pheochromocytomas (PCs) and paragangliomas (PGLs) with germline SDHx or VHL mutations have pseudohypoxic gene expression signatures. We hypothesised that PC/PGLs containing SDHx or VHL mutations, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours (GISTs), would overexpress miR-210 relative to non-SDH or -VHL-mutated counterparts. miR-210 was analysed by quantitative PCR in i) 39 PC/PGLs, according to genotype (one SDHA, five SDHB, seven VHL, three NF1, seven RET, 15 sporadic, one unknown) and pathology (18 benign, eight atypical, 11 malignant, two unknown); ii) 18 GISTs, according to SDHB immunoreactivity (nine SDH-deficient and nine SDH-proficient) and iii) two novel SDHB-mutant neurosphere cell lines. miR-210 was higher in SDHx- or VHL-mutated PC/PGLs (7.6-fold) compared with tumours without SDHx or VHL mutations (P=0.0016). miR-210 was higher in malignant than in unequivocally benign PC/PGLs (P=0.05), but significance was lost when benign and atypical tumours were combined (P=0.08). In multivariate analysis, elevated miR-210 was significantly associated with SDHx or VHL mutation, but not with malignancy. In GISTs, miR-210 was higher in SDH-deficient (median 2.58) compared with SDH-proficient tumours (median 0.60; P=0.0078). miR-210 was higher in patient-derived neurosphere cell lines containing SDHB mutations (6.5-fold increase) compared with normal controls, in normoxic conditions (P<0.01). Furthermore, siRNA-knockdown of SDHB in HEK293 cells increased miR-210 by 2.7-fold (P=0.001) under normoxia. Overall, our results suggest that SDH deficiency in PC, PGL and GISTs induces miR-210 expression and substantiates the role of aberrant hypoxic-type cellular responses in the development of these tumours.


Subject(s)
Adrenal Gland Neoplasms/genetics , Gastrointestinal Stromal Tumors/genetics , MicroRNAs/genetics , Mutation/genetics , Paraganglioma/genetics , Pheochromocytoma/genetics , Succinate Dehydrogenase/genetics , Adrenal Gland Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Child , Female , Follow-Up Studies , Gastrointestinal Stromal Tumors/pathology , Humans , Male , Middle Aged , Neoplasm Grading , Paraganglioma/pathology , Pheochromocytoma/pathology , Prognosis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Von Hippel-Lindau Tumor Suppressor Protein/genetics , Young Adult
6.
Intern Med J ; 43(2): 150-6, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22647225

ABSTRACT

BACKGROUND/AIM: The nuclear POLG gene encodes the catalytic subunit of DNA polymerase gamma (polγ), the only polymerase involved in the replication and proofreading of mitochondrial DNA. As a consequence, POLG mutations can cause disease through impaired replication of mitochondrial DNA. To date, over 150 different mutations have been identified, with a growing number of associated phenotypes described. The aim of this study was to determine the prevalence of POLG mutations in an adult population of Australian patients with mitochondrial disease, displaying symptoms commonly associated with POLG-related diseases. METHODS: The clinical presentations of 322 patients from a specialist adult mitochondrial disease clinic were reviewed. Nineteen exhibited a cluster of three or more predefined clinical manifestations suggestive of POLG-related disease: progressive external ophthalmoplegia, seizures and/or an abnormal electroencephalogram, neuropathy, ataxia, liver function abnormalities, migraine or dysphagia/dysarthria. Patients were screened for mutations by direct nucleotide sequencing of the coding and exon-flanking intronic regions of POLG. RESULTS: Five of the 19 patients (26%) displaying a phenotype suggestive of POLG-related disease were found to have informative POLG coding mutations (p.T851A, p.N468D, p.Y831C, p.G517V and novel p.P163S variant). Literature and analysis of these mutations revealed that two of these patients had pathogenic mutations known to cause POLG-related disease (patient #1: p.T851A and p.P163S; patient #2: p.T851A and p.N468D). CONCLUSIONS: We conclude that the prevalence of pathogenic POLG mutations in our selected adult Australian cohort with suggestive clinical manifestations was 10%. A further 16% of patients had POLG variants but are unlikely to be responsible for causing their disease.


Subject(s)
DNA-Directed DNA Polymerase/genetics , Mitochondrial Diseases/diagnosis , Mitochondrial Diseases/genetics , Mutation/genetics , Adult , Amino Acid Sequence , Australia/epidemiology , Cohort Studies , DNA Polymerase gamma , Female , Humans , Middle Aged , Mitochondrial Diseases/epidemiology , Molecular Sequence Data , Prevalence , Young Adult
7.
Intern Med J ; 42(12): 1342-7, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23252998

ABSTRACT

BACKGROUND: Hereditary spastic paraplegia (HSP) is often caused by mutations in the SPAST gene. The frequency of SPAST mutations causing HSP in Australian patients is currently unknown. AIM: We aimed to determine the frequency of SPAST gene mutations in our cohort of HSP patients. METHODS: We recruited 30 unrelated patients with HSP for clinical and genetic assessment. DNA or RNA was extracted from patients' samples to perform direct DNA sequencing of the SPAST gene, multiplex ligation-dependent probe amplification (MLPA) and/or cDNA analysis. RESULTS: We identified 13 heterozygous SPAST mutations in 16 unrelated patients. Most mutations (75%) were detected by DNA sequence analysis. We identified nine-point mutations (n = 9), insertion (n = 1), one type of splice site mutation (n = 2), one type of exonic deletion (n = 2) and one type of exonic amplification (n = 2). Missense mutations (n = 7) were the most frequent mutation type (44%). Heterozygous exonic deletion (n = 2) and heterozygous exonic amplification (n = 2) were identified by MLPA and cDNA screening (25%). We also identified the single heterozygous p.Ser44Leu polymorphism in two other patients without pathogenic mutations in SPAST. CONCLUSION: We conclude that SPAST mutations are responsible for the majority of HSP in Australia. Most of the patients with SPAST mutations had pure forms of HSP and a positive family history to suggest autosomal dominant (AD) HSP. Not all mutations were identified by direct sequencing of the SPAST gene, necessitating further molecular analysis. Given that SPAST mutations cause AD-HSP, these findings are important when providing genetic counselling for affected patients.


Subject(s)
Adenosine Triphosphatases/genetics , Spastic Paraplegia, Hereditary/genetics , DNA Mutational Analysis , Female , Gene Deletion , Humans , Male , Multiplex Polymerase Chain Reaction , Mutation, Missense , Polymorphism, Single Nucleotide , Spastin
8.
Parkinsonism Relat Disord ; 18(4): 386-90, 2012 May.
Article in English | MEDLINE | ID: mdl-22243833

ABSTRACT

Parkinson's disease (PD) is aetiologically complex with both familial and sporadic forms. Familial PD results from rare, highly penetrant pathogenic mutations whereas multiple variants of low penetrance may contribute to the risk of sporadic PD. Common variants implicated in PD risk appear to explain only a minor proportion of the familial clustering observed in sporadic PD. It is therefore plausible that combinations of rare and/or common variants in genes already implicated in disease pathogenesis may help to explain the genetic basis of PD. We have developed a CustomSeq Affymetrix resequencing array to enable high-throughput sequencing of 13 genes (44 kb) implicated in the pathogenesis of PD. Using the array we sequenced 269 individuals, including 186 PD patients and 75 controls, achieving an overall call rate of 96.5% and 93.6%, for two respective versions of the array, and >99.9% accuracy for five samples sequenced by capillary sequencing in parallel. We identified modest associations with common variants in SNCA and LRRK2 and a trend suggestive of an overrepresentation of rare variants in cases compared to controls for several genes. We propose that this technology offers a robust and cost-effective alternative to targeted sequencing using traditional sequencing methods, and here we demonstrate the potential of this approach for either routine clinical investigation or for research studies aimed at understanding the genetic aetiology of PD.


Subject(s)
Gene Expression Profiling , Genetic Predisposition to Disease , Oligonucleotide Array Sequence Analysis , Parkinson Disease/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Female , Genotype , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Male , Middle Aged , Phenotype , Protein Kinases/genetics , Protein Serine-Threonine Kinases/genetics , Reproducibility of Results , Ubiquitin-Protein Ligases/genetics , alpha-Synuclein/genetics
9.
Bone Marrow Transplant ; 46(3): 330-337, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20436523

ABSTRACT

Allogeneic hematopoietic SCT (HSCT) has been proposed as a treatment for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). HSCT has been performed in nine patients using different protocols with varying success. Based on this preliminary experience, participants of the first consensus conference propose a common approach to allogeneic HSCT in MNGIE. Standardization of the transplant protocol and the clinical and biochemical assessments will allow evaluation of the safety and efficacy of HSCT as well as optimization of therapy for patients with MNGIE.


Subject(s)
Stem Cell Transplantation/standards , Humans , Intestinal Pseudo-Obstruction/genetics , Intestinal Pseudo-Obstruction/surgery , Mitochondrial Encephalomyopathies/genetics , Mitochondrial Encephalomyopathies/surgery , Muscular Dystrophy, Oculopharyngeal , Ophthalmoplegia/congenital
10.
BMJ Case Rep ; 20092009.
Article in English | MEDLINE | ID: mdl-21731582

ABSTRACT

Charcot-Marie tooth disease (CMT) is a heterogenous group of peripheral neuropathies caused by various genetic defects. Three cases of mitochondrial myopathy, neuropathy and gastrointestinal encephalopathy (MNGIE) which initially presented with a peripheral neuropathy resembling CMT are described here. The diagnosis in all three cases was made after they developed eye signs and abdominal complaints. Young patients with mutation negative CMT should be followed up to monitor for signs of MNGIE.

11.
Hum Mutat ; 29(2): 331-2, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18205193

ABSTRACT

Myoclonus-dystonia (M-D) is an autosomal-dominant movement disorder caused by mutations in SGCE. We investigated the frequency and type of SGCE mutations with emphasis on gene dosage alterations and explored the associated phenotypes. We tested 35 M-D index patients by multiplex ligation-dependent probe amplification (MLPA) and genomic sequencing. Mutations were found in 26% (9/35) of the cases, all but three with definite M-D. Two heterozygous deletions of the entire SGCE gene and flanking DNA and a heterozygous deletion of exon 2 only were detected, accounting for 33% (3/9) of the mutations found. Both large deletions contained COL1A2 and were additionally associated with joint problems. Further, we discovered one novel small deletion (c.771_772delAT, p.C258X) and four recurrent point mutations (c.289C>T, p.R97X; c.304C>T, p.R102X; c.709C>T, p.R237X; c.1114C>T, p.R372X). A Medline search identified 22 articles on SGCE mutational screening. Sixty-four unrelated M-D patients were described with 41 different mutations. No genotype-phenotype association was found, except in patients with deletions encompassing additional genes. In conclusion, a rigorous clinical preselection of patients and careful accounting for non-motor signs should precede mutational tests. Gene dosage studies should be included in routine SGCE genetic testing.


Subject(s)
Gene Deletion , Myoclonus/genetics , Sarcoglycans/genetics , Adolescent , Adult , Aged , Base Sequence , Child , Child, Preschool , DNA Mutational Analysis , Demography , Exons/genetics , Female , Genome, Human , Humans , Male , Middle Aged , Molecular Sequence Data , Pedigree , Phenotype , Review Literature as Topic
12.
Intern Med J ; 37(12): 812-4, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17561942

ABSTRACT

BACKGROUND: Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting older individuals. Few studies have determined the prevalence and incidence of this disease in Australia. The aim of the study was to estimate the prevalence and 10-year incidence of PD in the Australian community. METHODS: In the Blue Mountains Eye Study (BMES), a population-based health survey of Australian residents aged 49 years or more, we determined the cross-sectional prevalence (BMES2, 1997-1999, n = 3509) and 10-year incidence (BMES1, 2 and 3, 1992-1994, 1997-1999 and 2002-2004, respectively, n = 2545) of PD. We screened participants who took PD medications. PD diagnosis was confirmed by contacting the participant's medical/general practitioners. RESULTS: Nineteen new cases of PD were identified over the 10-year period, a 10-year incidence of 0.84% (95% confidence interval (CI) 0.54-1.33%). In the cross-sectional study, 16/3509 participants were confirmed to have PD (0.46%), with age-specific prevalence rates of 0.48% in persons aged 60-69 years, 0.82% for ages 70-79 years and 0.56% in persons aged 80 years or older. No PD cases were identified among participants less than 60 years of age. When age standardized to the 2001 Australian population, the prevalence of PD was 362 per 100,000 (95%CI 183-541) among persons aged 50 years or older and 104 per 100,000 for the Australian population at all ages, assuming no prevalent cases in persons aged less than 50 years. CONCLUSION: This study estimates a 0.46% (95%CI 0.23-0.68) prevalence of PD patients treated with medications aged 50 years or older and a 10-year incidence of 0.84% (95%CI 0.54-1.33).


Subject(s)
Parkinson Disease/diagnosis , Parkinson Disease/epidemiology , Aged , Aged, 80 and over , Antiparkinson Agents/therapeutic use , Australia , Cross-Sectional Studies , Female , Humans , Incidence , Male , Middle Aged , Parkinson Disease/drug therapy , Prevalence
14.
Intern Med J ; 36(8): 530-3, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16866660

ABSTRACT

Mitochondrial DNA (mtDNA) haplogroups are 'neutral polymorphisms' in the mtDNA genome, which have accumulated and persisted along maternal lineages as the human population has migrated worldwide. Three ethnically distinct lineages of human mtDNA populations have been identified: European, characterized by nine haplogroups H, I, J, K, T, U, V, W and X; African, characterized by superhaplogroup L and Asian, characterized by superhaplogroup M. We studied the prevalence of mtDNA haplogroups in participants of the Blue Mountains Eye Study, a large population-based survey of vision conducted between 1991 and 2000 of non-institutionalized permanent residents aged 49 years or older from two suburban postcode areas, west of Sydney, Australia. Total DNA isolated from either hair follicles or blood was available for 3377 of the 3509 participants (96.2%) to determine mtDNA haplogroups by polymerase chain reaction/restriction fragment length polymorphism analysis. Approximately 94.2% of samples could be assigned to one of the nine major European haplogroups, whereas a further 1.2% included the African (L) and Asian (M) superhaplogroups. The five principal haplogroups represented were H (42.9%), U (14.1%), J (10.7%), T (9.2%) and K (8.1%), which together included 85% of this population.


Subject(s)
DNA, Mitochondrial/genetics , Haplotypes/genetics , Racial Groups/genetics , Female , Genetic Markers/genetics , Humans , Male , Middle Aged , New South Wales , Polymorphism, Genetic/genetics , Prevalence
15.
J Inherit Metab Dis ; 29(1): 86-91, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16601873

ABSTRACT

Mitochondrial diseases are a heterogeneous group of disorders caused by mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Mitochondrial disease leads to impaired respiratory chain function and reduced ATP production. The aim of this study was to compare disturbances in mitochondrial function by measuring ATP synthesis in fibroblasts derived from patients with nDNA and mtDNA defects. Skin fibroblasts derived from 22 patients with either nDNA-related disorders (n = 8) or mtDNA-related disorders (n = 14) were analysed. ATP synthesis was markedly decreased in fibroblasts derived from patients with nDNA-related disorders but only variably so in patients with mtDNA mutations. In fibroblasts with the MELAS 3243A > G mutation, ATP synthesis correlated with mutant load. We believe that the observed differences in ATP production between cell lines derived from patients with nDNA-related disorders and mtDNA-related disorders may help in the assessment of patients with undiagnosed mitochondrial disease. The clinical comparisons observed in patients with nDNA- and mtDNA-related disorders may be explained by differences in the disturbance of ATP synthesis measured in the two conditions.


Subject(s)
Adenosine Triphosphate/biosynthesis , Mitochondrial Diseases/diagnosis , Mitochondrial Diseases/genetics , Mitochondrial Diseases/metabolism , Mutation , Adenosine Triphosphate/metabolism , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Fibroblasts/metabolism , Humans , Infant , MELAS Syndrome/genetics , Male , Middle Aged
16.
J Child Neurol ; 16(7): 531-3, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11453453

ABSTRACT

We describe a 5-year-old child with hypertrophic cardiomyopathy, mitochondrial myopathy, and lactic acidosis. Mitochondrial DNA analysis showed a heteroplasmic A5814G point mutation in the tRNA(Cys) gene. The mutational load was extremely high (>95%) in muscle, fibroblasts, and blood. This report expands the clinical heterogeneity of the A5814G mutation, which should be considered in the differential diagnosis of hypertrophic cardiomyopathy in childhood.


Subject(s)
Acidosis, Lactic/genetics , Cardiomyopathy, Hypertrophic, Familial/genetics , DNA, Mitochondrial/genetics , Mitochondrial Myopathies/genetics , Point Mutation , Acidosis, Lactic/pathology , Cardiomyopathy, Hypertrophic, Familial/pathology , Child, Preschool , Diagnosis, Differential , Humans , Male , Mitochondrial Myopathies/pathology
17.
J Child Neurol ; 15(11): 759-61, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11108511

ABSTRACT

We identified a G-->A transition at nt-8363 in the mitochondrial DNA transfer ribonucleic acidLys gene in blood and muscle from a 13-month-old girl who had clinical and neuroradiologic evidence of Leigh syndrome and died at age 27 months. The mutation was less abundant in the same tissues from the patient's mother, who developed myoclonus epilepsy with ragged red fibers (MERRF) in her late 20s. In both mother and daughter, muscle histochemistry showed ragged red and cytochrome c oxidase-negative fibers and biochemical analysis showed partial defects of multiple respiratory-chain enzymes. A maternal half-sister of the proband had died at 2.5 years of age from neuropathologically proven Leigh syndrome. The G8363A mutation, which previously had been associated with cardiomyopathy and hearing loss, MERRF, and multiple lipomas, also should be included in the differential diagnosis of maternally inherited Leigh syndrome.


Subject(s)
DNA, Mitochondrial/genetics , Leigh Disease/genetics , MERRF Syndrome/genetics , Muscle Fibers, Skeletal/pathology , Mutation, Missense , RNA, Transfer, Lys/genetics , Adult , Child, Preschool , Diagnosis, Differential , Electron Transport Complex IV/analysis , Fatal Outcome , Female , Genotype , Humans , Immunohistochemistry , Infant , Leigh Disease/complications , Leigh Disease/diagnosis , Leigh Disease/pathology , MERRF Syndrome/complications , MERRF Syndrome/diagnosis , MERRF Syndrome/pathology , Muscle Fibers, Skeletal/chemistry , Muscle, Skeletal/pathology , Pedigree
18.
Nature ; 406(6798): 906-10, 2000 Aug 24.
Article in English | MEDLINE | ID: mdl-10972294

ABSTRACT

"Lysosomal glycogen storage disease with normal acid maltase" which was originally described by Danon et al., is characterized clinically by cardiomyopathy, myopathy and variable mental retardation. The pathological hallmark of the disease is intracytoplasmic vacuoles containing autophagic material and glycogen in skeletal and cardiac muscle cells. Sarcolemmal proteins and basal lamina are associated with the vacuolar membranes. Here we report ten unrelated patients, including one of the patients from the original case report, who have primary deficiencies of LAMP-2, a principal lysosomal membrane protein. From these results and the finding that LAMP-2-deficient mice manifest a similar vacuolar cardioskeletal myopathy, we conclude that primary LAMP-2 deficiency is the cause of Danon disease. To our knowledge this is the first example of human cardiopathy-myopathy that is caused by mutations in a lysosomal structural protein rather than an enzymatic protein.


Subject(s)
Cardiomyopathies/etiology , Lysosomal Storage Diseases/etiology , Membrane Glycoproteins/deficiency , Muscular Diseases/etiology , X Chromosome , Antigens, CD/genetics , Antigens, CD/physiology , Blotting, Western , Cardiomyopathies/genetics , Cardiomyopathies/pathology , DNA Mutational Analysis , Female , Genetic Linkage , Humans , Immunohistochemistry , Lysosomal Storage Diseases/genetics , Lysosomal Storage Diseases/pathology , Lysosomal Membrane Proteins , Male , Membrane Glycoproteins/genetics , Membrane Glycoproteins/physiology , Molecular Sequence Data , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Diseases/genetics , Muscular Diseases/pathology , Sequence Analysis, DNA , Vacuoles/pathology
19.
Neurology ; 55(5): 644-9, 2000 Sep 12.
Article in English | MEDLINE | ID: mdl-10980727

ABSTRACT

OBJECTIVE: To elucidate the molecular basis of a mitochondrial myopathy associated with recurrent myoglobinuria and cytochrome c oxidase (COX) deficiency in muscle. BACKGROUND: Recurrent myoglobinuria is typically seen in patients with inborn errors of carbohydrate or lipid metabolism, the main sources of energy for muscle contraction. Relatively little attention has been directed to defects of the mitochondrial respiratory chain in patients with otherwise unexplained recurrent myoglobinuria. METHODS: Having documented COX deficiency histochemically and biochemically in the muscle biopsy from a patient with exercise-induced recurrent myoglobinuria, the authors sequenced the three mitochondrial DNA (mtDNA)-encoded COX genes, and performed restriction fragment length polymorphism analysis and single-fiber PCR. RESULTS: The authors identified a nonsense mutation (G5920A) in the COX I gene in muscle mtDNA. The mutation was heteroplasmic and abundantly present in COX-negative fibers, but less abundant or absent in COX-positive fibers; it was not found in blood or fibroblasts from the patient or in blood samples from the patient's asymptomatic mother and sister. CONCLUSIONS: The G5920A mutation caused COX deficiency in muscle, explaining the exercise intolerance and the low muscle capacity for oxidative phosphorylation documented by cycle ergometry. The sporadic occurrence of this mutation in muscle alone suggests that it arose de novo in myogenic stem cells after germ-layer differentiation. Mutations in mtDNA-encoded COX genes should be considered in patients with recurrent myoglobinuria.


Subject(s)
DNA, Mitochondrial/genetics , Electron Transport Complex IV/genetics , Mutation/genetics , Myoglobinuria/etiology , Myoglobinuria/genetics , Adult , Humans , Immunohistochemistry , Male , Muscles/pathology , Myoglobinuria/physiopathology , Polymorphism, Restriction Fragment Length , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...